References
- Moran AE, Kovacsovics-Bankowski M, Weinberg AD. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol. 2013;25:230–10. doi:https://doi.org/10.1016/j.coi.2013.01.004.
- Buchan SL, Dou L, Remer M, Booth SG, Dunn SN, Lai C, Semmrich M, Teige I, Martensson L, Penfold CA, et al. Antibodies to costimulatory receptor 4-1BB enhance anti-tumor immunity via T regulatory cell depletion and promotion of CD8 T cell effector function. Immunity. 2018;49:958–70.e7. doi:https://doi.org/10.1016/j.immuni.2018.09.014.
- Chester C, Sanmamed MF, Wang J, Melero I. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood. 2018;131:49–57. doi:https://doi.org/10.1182/blood-2017-06-741041.
- Vonderheide RH. CD40 agonist antibodies in cancer immunotherapy. Annu Rev Med. 2019. doi:https://doi.org/10.1146/annurev-med-062518-045435.
- Martin-Villalba A, Llorens-Bobadilla E, Wollny D. CD95 in cancer: tool or target? Trends Mol Med. 2013;19:329–35. doi:https://doi.org/10.1016/j.molmed.2013.03.002.
- von Karstedt S, Montinaro A, Walczak H. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer. 2017;17:352–66. doi:https://doi.org/10.1038/nrc.2017.28.
- Zamagni E, Tacchetti P, Pantani L, Cavo M. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy. Expert Rev Hematol. 2018;11:423–35. doi:https://doi.org/10.1080/17474086.2018.1456331.
- Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018;9:1821. doi:https://doi.org/10.3389/fimmu.2018.01821.
- Bensinger W, Maziarz RT, Jagannath S, Spencer A, Durrant S, Becker PS, Ewald B, Bilic S, Rediske J, Baeck J, et al. A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol. 2012;159:58–66. doi:https://doi.org/10.1111/j.1365-2141.2012.09251.x.
- Hussein M, Berenson JR, Niesvizky R, Munshi N, Matous J, Sobecks R, Harrop K, Drachman JG, Whiting N. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica. 2010;95:845–48. doi:https://doi.org/10.3324/haematol.2009.008003.
- Locksley RM, Killeen N, Lenardo MJ, The TNF. TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487–501. doi:https://doi.org/10.1016/s0092-8674(01)00237-9.
- Medler J, Wajant H. Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target. Expert Opin Ther Targets. 2019;23:295–307. doi:https://doi.org/10.1080/14728222.2019.1586886.
- Wajant H. Principles of antibody-mediated TNF receptor activation. Cell Death Differ. 2015;22:1727–41. doi:https://doi.org/10.1038/cdd.2015.109.
- Piechutta M, Berghoff AS. New emerging targets in cancer immunotherapy: the role of cluster of differentiation 40 (CD40/TNFR5). ESMO Open. 2019;4:e000510. doi:https://doi.org/10.1136/esmoopen-2019-000510.
- Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature. 1993;364:806–09. doi:https://doi.org/10.1038/364806a0.
- Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH, Runkel L. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med. 1995;182:1223–30. doi:https://doi.org/10.1084/jem.182.5.1223.
- Xu Y, Szalai AJ, Zhou T, Zinn KR, Chaudhuri TR, Li X, Koopman WJ, Kimberly RP. Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol. 2003;171:562–68. doi:https://doi.org/10.4049/jimmunol.171.2.562.
- Jodo S, Kung JT, Xiao S, Chan DV, Kobayashi S, Tateno M, Lafyatis R, Ju ST. Anti-CD95-induced lethality requires radioresistant Fcgamma RII+ cells. A novel mechanism for fulminant hepatic failure. J Biol Chem. 2003;278:7553–57. doi:https://doi.org/10.1074/jbc.M211229200.
- Li F, Ravetch JV. Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science. 2011;333:1030–34. doi:https://doi.org/10.1126/science.1206954.
- Li F, Ravetch JV. Antitumor activities of agonistic anti-TNFR antibodies require differential FcgammaRIIB coengagement in vivo. Proc Natl Acad Sci USA. 2013;110:19501–06. doi:https://doi.org/10.1073/pnas.1319502110.
- Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV. Therapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective FcgammaR engagement. Cancer Cell. 2016;29:820–31. doi:https://doi.org/10.1016/j.ccell.2016.05.001.
- Clark EA, Yip TC, Ledbetter JA, Yukawa H, Kikutani H, Kishimoto T, Ng MH. CDw40 and BLCa-specific monoclonal antibodies detect two distinct molecules which transmit progression signals to human B lymphocytes. Eur J Immunol. 1988;18:451–57. doi:https://doi.org/10.1002/eji.1830180320.
- Chodorge M, Zuger S, Stirnimann C, Briand C, Jermutus L, Grutter MG, Minter RR. A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency. Cell Death Differ. 2012;19:1187–95. doi:https://doi.org/10.1038/cdd.2011.208.
- Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009;9:491–502. doi:https://doi.org/10.1038/nri2572.
- Tai YT, Anderson KC. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. Expert Opin Biol Ther. 2019;19:1143–56. doi:https://doi.org/10.1080/14712598.2019.1641196.
- Francisco JA, Donaldson KL, Chace D, Siegall CB, Wahl AF. Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14. Cancer Res. 2000;60:3225–31.
- Tai YT, Li X, Tong X, Santos D, Otsuki T, Catley L, Tournilhac O, Podar K, Hideshima T, Schlossman R, et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005;65:5898–906. doi:https://doi.org/10.1158/0008-5472.Can-04-4125.
- Horton HM, Bernett MJ, Peipp M, Pong E, Karki S, Chu SY, Richards JO, Chen H, Repp R, Desjarlais JR, et al. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood. 2010;116:3004–12. doi:https://doi.org/10.1182/blood-2010-01-265280.
- Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res. 2005;65:8331–38. doi:https://doi.org/10.1158/0008-5472.Can-05-0095.
- Askenasy N, Yolcu ES, Yaniv I, Shirwan H. Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood. 2005;105:1396–404. doi:https://doi.org/10.1182/blood-2004-06-2364.
- Igney FH, Behrens CK, Krammer PH. Tumor counterattack–concept and reality. Eur J Immunol. 2000;30:725–31. doi:https://doi.org/10.1002/1521-4141(200003)30:3<725::Aid-immu725>3.0.Co;2-d.
- Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19:2048–60. doi:https://doi.org/10.1158/1078-0432.Ccr-12-2422.
- Moreaux J, Hose D, Jourdan M, Reme T, Hundemer M, Moos M, Robert N, Moine P, De Vos J, Goldschmidt H, et al. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines. Haematologica. 2007;92:803–11. doi:https://doi.org/10.3324/haematol.10574.
- Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, Gross JA, Greipp PR, Jelinek DF. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004;103:689–94. doi:https://doi.org/10.1182/blood-2003-06-2043.
- Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688–700. doi:https://doi.org/10.1182/blood-2016-04-711903.
- Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson LD Jr., Sutherland HJ, Yong K, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19:1641–53. doi:https://doi.org/10.1016/s1470-2045(18)30576-x.
- Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Hoos A, Gupta I, Bragulat V, et al. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019;9:37. doi:https://doi.org/10.1038/s41408-019-0196-6.
- Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, Stetler-Stevenson M, Salem D, Yuan C, Pavletic S, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36:2267–80. doi:https://doi.org/10.1200/jco.2018.77.8084.
- Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, Zhang YL, Wang FX, Zhang PY, Lei B, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11:141. doi:https://doi.org/10.1186/s13045-018-0681-6.
- Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129:2210–21. doi:https://doi.org/10.1172/jci126397.
- Curran KJ, Seinstra BA, Nikhamin Y, Yeh R, Usachenko Y, van Leeuwen DG, Purdon T, Pegram HJ, Brentjens RJ. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther. 2015;23:769–78. doi:https://doi.org/10.1038/mt.2015.4.
- Kuhn NF, Purdon TJ, van Leeuwen DG, Lopez AV, Curran KJ, Daniyan AF, Brentjens RJ. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell. 2019;35:473–88.e6. doi:https://doi.org/10.1016/j.ccell.2019.02.006.
- Wyzgol A, Muller N, Fick A, Munkel S, Grigoleit GU, Pfizenmaier K, Wajant H. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol. 2009;183:1851–61. doi:https://doi.org/10.4049/jimmunol.0802597.
- Lang I, Fullsack S, Wyzgol A, Fick A, Trebing J, Arana JA, Schafer V, Weisenberger D, Wajant H. Binding studies of TNF receptor superfamily (TNFRSF) receptors on intact cells. J Biol Chem. 2016;291:5022–37. doi:https://doi.org/10.1074/jbc.M115.683946.
- Kums J, Nelke J, Ruth B, Schafer V, Siegmund D, Wajant H. Quantitative analysis of cell surface antigen-antibody interaction using Gaussia princeps luciferase antibody fusion proteins. MAbs. 2017;9:506–20. doi:https://doi.org/10.1080/19420862.2016.1274844.